転移性去勢抵抗性前立腺癌患者におけるctDNAの縦断的分子変化の特徴付け

Circulating tumor DNA (ctDNA) NGS complements tissue-based testing and offers insights into prognosis, treatment selection, and tumor evolution. Despite advances in mCRPC therapies, resistance remains a challenge. This real-world study evaluates longitudinal ctDNA changes following systemic treatments.

We analyzed data from GuardantINFORM, a clinical-genomic database linking ctDNA profiles with claims data. Patients with prostate cancer who received ARPi, PARPi, or taxanes and had ctDNA testing within 3 months before and after treatment discontinuation were included. We evaluated pre- and post-treatment mutational differences and survival outcomes [Overall Survival (OS), Time to treatment discontinuation (TTD), Time to new treatment (TTNT)], stratifying by treatment type and AR alterations.

From 36,774 prostate-cancer patients, we identified 678 with paired pre/post-ARPi, 188 with paired pre/post-PARPi, and 844 with paired pre/post-taxane ctDNA samples. Post-ARPi, the most frequent AR alterations included AR amplification (pre%/post%) (10.8%/25.6%), AR L702H (1.3%/7.9%), and AR T878A (2.9%/7.1%). Following PARPi, the most common HRR gene alterations were ATM (25%/23.4%), BRCA2 (22.9%/17%), BRCA1 (4%/2.1%), and CDK12 (5.9%/5.9%). Post-taxane, frequent alterations included TP53 (47.2%→54%), AR (33.2%/49.9%), PIK3CA (9.4%/15.9%), and EGFR (9.6%/14.6%). All treatment cohorts showed a significant increase in mutation burden post-therapy (mean increase 2.0-4.2 alterations; p<0.001). Across all three treatment groups, the presence of AR alterations was consistently associated with inferior clinical outcomes.

Our study revealed dynamic shifts in genetic mutations in patients with mCRPC following ARPI, PARPi and taxanes. Furthermore, our findings highlight associations between AR alterations and clinical outcomes, emphasizing the potential for personalized treatment strategies.